Low dose colchicine significantly reduces the risk of cardiovascular events in patients with chronic coronary disease, Australian researchers say. The findings of the LoDoCo2 study, presented at the European Society of Cardiology Congress (ESC 2020 virtual meeting) and published in the NEJM, support the repurposing of colchicine for routine secondary prevention in this patient group, ...
Colchicine the third cornerstone of preventive therapy for coronary disease: LoDoCo2
By Mardi Chapman
1 Sep 2020